CAGRISEMA vs RETATRUTIDE

Side-by-side comparison of cagrisema and retatrutide. Effects, dosage, side effects, community sentiment, and research.

For informational purposes only. Not medical advice. Always consult a healthcare professional.

Quick Verdict

Weight Loss RETATRUTIDE Both target weight loss. RETATRUTIDE has a higher community sentiment score (70 vs 62).
Stack compatibility

Both target similar goals (Weight Loss) through potentially different mechanisms. Research interactions before stacking.

At a Glance

CAGRISEMA
Peptide / GLP 62/100 Mixed 4 studies
Weight Loss

CagriSema is a fixed-dose combination injectable peptide consisting of semaglutide 2.4 mg (a GLP-1 receptor agonist) and cagrilintide 2.4 mg (a long-acting amyl...

VS
RETATRUTIDE
Peptide / GLP 70/100 Positive 5 studies
Weight Loss

Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. In clinical trials, it produced unprecedented weight loss results, making it...

Detailed Comparison

CAGRISEMA RETATRUTIDE
Category Peptide, GLP Peptide, GLP
Sentiment 62/100 (Mixed) 70/100 (Positive)
Use Cases Weight Loss Weight Loss
Key Effects
  • Dual Pathway Action: Combines amylin-mediated satiety and gastric emptying with GLP-1 appetite suppression and insulin secretion for additive weight loss.
  • Significant Weight Reduction: 20-23% body weight loss over 68-84 weeks in non-diabetic adults with obesity.
  • Glycemic Control: Lowers HbA1c by 1.5-2.2 percentage points in people with type 2 diabetes.
  • Dramatic Weight Loss: Up to 24% body weight reduction in trials.
  • Triple Action: Targets GLP-1, GIP, and glucagon receptors.
  • Metabolic Improvement: Better glucose control and metabolic health.
Dosage
  • Maintenance Dose: Cagrilintide 2.4 mg + semaglutide 2.4 mg, once weekly subcutaneous injection.
  • Titration Schedule: Starts at 0.25 mg/week, escalating through 0.5 mg, 1.0 mg, 1.7 mg over 16 weeks to reach maintenance 2.4 mg at week 17.
  • Clinical Trial Doses: 1-12mg weekly in phase 2 trials.
  • Weekly Injection: Administered once weekly.
Side Effects
  • GI Events: 79.6% of CagriSema users experienced gastrointestinal adverse events vs 39.9% on placebo.
  • Nausea: Most common side effect at 55%, usually mild-to-moderate and diminishing during titration.
  • Constipation and Vomiting: Reported in 30.7% and 26.1% of users respectively.
  • GI Effects: Nausea, vomiting, diarrhea common.
  • Similar to GLP-1s: Side effect profile comparable to semaglutide.
  • Dose-Related: Higher doses mean more side effects.
Studies 4 published studies 5 published studies

Community Sentiment

CAGRISEMA

62/100

Strong initial excitement after REDEFINE 1/2 results showing superior weight loss over semaglutide alone, but sentiment cooled after the February 2026 REDEFINE 4 trial failed to demonstrate noninferiority against tirzepatide (Zepbound). Still demonstrates clinically meaningful 23% weight loss and remains on track for potential FDA approval.

RETATRUTIDE

70/100

Early adopters report dramatic weight loss exceeding semaglutide results. Side effects similar to other GLP-1 agonists. Not yet FDA approved but generating significant interest.

Research Studies

CAGRISEMA (4 studies)

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

REDEFINE 1 phase 3a trial in 3,417 adults showed CagriSema achieved 22.7% mean weight loss at 68 weeks, superior to semaglutide alone (14.9%) and cagrilintide alone (11.5%). 60% of participants lost at least 20% of body weight.

NEJM
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

REDEFINE 2 trial in 1,206 adults with T2D across 12 countries. CagriSema achieved 15.7% weight loss and 73.5% of patients reached HbA1c of 6.5% or lower vs 15.9% on placebo.

PubMed
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial

32-week trial in 92 participants with T2D. CagriSema achieved 15.6% weight loss vs 5.1% with semaglutide alone and 8.1% with cagrilintide alone. HbA1c reduction was 2.2 percentage points.

The Lancet
View all CAGRISEMA research →

RETATRUTIDE (5 studies)

Retatrutide, A Trigonal Glp-1, Gip And Glucagon Receptor Agonist, And Its Role In Weight Reduction

Study found retatrutide significantly reduces weight, waist circumference, and BMI in overweight adults while improving cardiometabolic parameters.

ScienceDirect
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial

Retatrutide significantly improved blood sugar control and reduced body weight across various doses, demonstrating higher effectiveness than placebo and dulaglutide.

ScienceDirect
The Effect Of Triple-Hormone-Receptor Agonist Retatrutide, A Novel Medication For Weight Loss, On Blood Pressure

Retatrutide showed potential to significantly lower both systolic and diastolic blood pressure based on phase 2 trials.

ScienceDirect
View all RETATRUTIDE research →

Frequently Asked Questions

Is CAGRISEMA or RETATRUTIDE better?

Based on aggregated community sentiment, RETATRUTIDE has a higher satisfaction score (70/100 Positive) compared to CAGRISEMA (62/100 Mixed). The better choice depends on your specific goals — review the per-goal comparison above.

Can you take CAGRISEMA and RETATRUTIDE together?

CAGRISEMA and RETATRUTIDE are sometimes used together, but safety data on this combination may be limited. Always consult a healthcare professional before combining any compounds. Check our protocols section for researched stacks.

What is the difference between CAGRISEMA and RETATRUTIDE?

CAGRISEMA is a Peptide/GLP primarily used for weight loss. RETATRUTIDE is a Peptide/GLP primarily used for weight loss. They differ in mechanism of action, dosage protocols, and side effect profiles. See the detailed comparison above.

Which is better for weight loss: CAGRISEMA or RETATRUTIDE?

For weight loss, both CAGRISEMA and RETATRUTIDE are commonly used. Community data suggests RETATRUTIDE has higher overall satisfaction (70/100). However, individual responses vary — what works best depends on your specific situation and biochemistry.

Full Compound Profiles

CAGRISEMA View full profile → RETATRUTIDE View full profile →
← Compare other compounds | + Add a third compound